Suppr超能文献

埃及患者布加氏综合征的流行病学特征:单中心研究。

Epidemiological aspects of Budd-Chiari in Egyptian patients: a single-center study.

机构信息

Department of Tropical Medicine, Faculty of Medicine, Ain Shams University, Abbassia, Cairo 11341, Egypt.

出版信息

World J Gastroenterol. 2011 Nov 14;17(42):4704-10. doi: 10.3748/wjg.v17.i42.4704.

Abstract

AIM

To describe the socio-demographic features, etiology, and risk factors for Budd-Chiari syndrome (BCS) in Egyptian patients.

METHODS

Ninety-four Egyptian patients with confirmed primary Budd-Chiari syndrome were presented to the Budd-Chiari Study Group (BCSG) and admitted to the Tropical Medicine Department of Ain Shams University Hospital (Cairo, Egypt). Complete clinical evaluation and laboratory investigations, including a thrombophilia workup and full radiological assessment, were performed to determine underlying disease etiologies.

RESULTS

BCS was chronic in 79.8% of patients, acute or subacute in 19.1%, and fulminant in 1.1%. Factor V Leiden mutation (FVLM) was the most common etiological cause of disease (53.1%), followed by mutation of the gene encoding methylene tetrahydrofolate reductase (MTHFR) (51.6%). Current or recent hormonal treatment was documented in 15.5% of females, and BCS associated with pregnancy was present in 17.2% of females. Etiology could not be determined in 8.5% of patients. Males had significantly higher rates of MTHFR gene mutation and Behçet's disease, and females had significantly higher rates of secondary antiphospholipid antibody syndrome. A highly significant positive relationship was evident between the presence of Behçet's disease and inferior vena caval occlusion, either alone or combined with occlusion of the hepatic veins (P < 0.0001).

CONCLUSION

FVLM is the most common disease etiology and MTHFR the second most common in Egyptian BCS patients. BCS etiology tends to vary with geographic region.

摘要

目的

描述埃及患者布加氏综合征(BCS)的社会人口学特征、病因和危险因素。

方法

94 例经证实的原发性布加氏综合征埃及患者被介绍给布加氏综合征研究小组(BCSG),并入住埃及开罗艾因沙姆斯大学医院热带医学系。进行了完整的临床评估和实验室检查,包括血栓形成倾向检查和全面的影像学评估,以确定潜在的疾病病因。

结果

BCS 慢性占 79.8%,急性或亚急性占 19.1%,暴发性占 1.1%。FVLM 是最常见的病因(53.1%),其次是编码亚甲基四氢叶酸还原酶(MTHFR)的基因突变(51.6%)。15.5%的女性有当前或近期激素治疗史,17.2%的女性有与妊娠相关的 BCS。8.5%的患者病因无法确定。男性 MTHFR 基因突变和 Behcet 病的发生率明显较高,女性继发性抗磷脂抗体综合征的发生率明显较高。Behcet 病的存在与下腔静脉阻塞(无论是单独存在还是与肝静脉阻塞同时存在)之间存在高度显著的正相关关系(P<0.0001)。

结论

FVLM 是埃及 BCS 患者最常见的疾病病因,MTHFR 是第二常见的病因。BCS 的病因倾向于因地理位置而异。

相似文献

1
Epidemiological aspects of Budd-Chiari in Egyptian patients: a single-center study.
World J Gastroenterol. 2011 Nov 14;17(42):4704-10. doi: 10.3748/wjg.v17.i42.4704.
4
Factor V G1691A (Leiden) is a major etiological factor in Egyptian Budd-Chiari syndrome patients.
Turk J Haematol. 2011 Dec 5;28(4):299-305. doi: 10.5152/tjh.2011.84.
7
Inherited prothrombotic defects in Budd-Chiari syndrome and portal vein thrombosis: a study from North India.
Am J Clin Pathol. 2004 Jun;121(6):844-7. doi: 10.1309/F2U1-XBV4-RXYU-AYG0.
8
Characteristics and outcome of primary Budd-Chiari syndrome due to Behçet's syndrome.
Clin Res Hepatol Gastroenterol. 2020 Sep;44(4):503-512. doi: 10.1016/j.clinre.2019.10.006. Epub 2019 Nov 14.
9
Factor V Leiden related Budd-Chiari syndrome.
Gut. 2001 Feb;48(2):264-8. doi: 10.1136/gut.48.2.264.

引用本文的文献

3
Budd-Chiari syndrome: consensus guidance of the Asian Pacific Association for the study of the liver (APASL).
Hepatol Int. 2021 Jun;15(3):531-567. doi: 10.1007/s12072-021-10189-4. Epub 2021 Jul 8.
4
Epidemiological Characteristics and Etiology of Budd-Chiari Syndrome in Upper Egypt.
J Blood Med. 2020 Dec 30;11:515-524. doi: 10.2147/JBM.S278678. eCollection 2020.
5
Budd-Chiari syndrome in Behcet's disease: A report of two cases.
Exp Ther Med. 2019 Mar;17(3):1737-1741. doi: 10.3892/etm.2018.7130. Epub 2018 Dec 24.
6
Budd-Chiari syndrome/hepatic venous outflow tract obstruction.
Hepatol Int. 2018 Feb;12(Suppl 1):168-180. doi: 10.1007/s12072-017-9810-5. Epub 2017 Jul 6.
7
Validation of prognostic indices in Egyptian Budd-Chiari syndrome patients: A single-center study.
World J Gastroenterol. 2017 Jan 28;23(4):629-637. doi: 10.3748/wjg.v23.i4.629.
8
Redefining Budd-Chiari syndrome: A systematic review.
World J Hepatol. 2016 Jun 8;8(16):691-702. doi: 10.4254/wjh.v8.i16.691.
9
Prevalence of Budd-Chiari Syndrome during Pregnancy or Puerperium: A Systematic Review and Meta-Analysis.
Gastroenterol Res Pract. 2015;2015:839875. doi: 10.1155/2015/839875. Epub 2015 Sep 20.
10
Budd-Chiari Syndrome in a Patient with JAK-2 V617F and Factor V G1691A Mutations.
West Indian Med J. 2014 Sep;63(5):528-31. doi: 10.7727/wimj.2013.228. Epub 2014 Jun 10.

本文引用的文献

1
Primary Budd-Chiari syndrome.
J Hepatol. 2009 Jan;50(1):195-203. doi: 10.1016/j.jhep.2008.10.007. Epub 2008 Oct 26.
2
Occurrence of the JAK2 V617F mutation in the Budd-Chiari syndrome.
Blood Coagul Fibrinolysis. 2008 Jul;19(5):459-62. doi: 10.1097/MBC.0b013e3283049662.
3
Budd-Chiari syndrome and veno-occlusive disease/sinusoidal obstruction syndrome.
Gut. 2008 Oct;57(10):1469-78. doi: 10.1136/gut.2007.133637. Epub 2008 Jun 26.
4
Etiology and portal vein thrombosis in Budd-Chiari syndrome.
World J Gastroenterol. 2008 May 14;14(18):2858-62. doi: 10.3748/wjg.14.2858.
5
The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases.
Blood. 2008 May 15;111(10):4922-9. doi: 10.1182/blood-2007-11-125328. Epub 2008 Feb 4.
6
Phenotype and genotype in the myeloproliferative disorders.
Eur J Haematol Suppl. 2007 Oct(68):9-12. doi: 10.1111/j.1600-0609.2007.00936.x.
8
The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis.
J Thromb Haemost. 2007 Jan;5(1):55-61. doi: 10.1111/j.1538-7836.2006.02277.x. Epub 2006 Oct 20.
9
Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome.
Gastroenterology. 2006 Jun;130(7):2031-8. doi: 10.1053/j.gastro.2006.04.008.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验